{"id":"W4286299145","doi":"10.1200/jco.2022.40.16_suppl.7015","title":"Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Clinical endpoint; Internal medicine; Adverse effect; Phases of clinical research; Anemia; Gastroenterology; Clinical trial; Oncology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002198501,0.001634269,0.002186336,0.0004209025,0.0004368094,0.001172969,0.0008326795,0.001176869,0.003000065],"category_scores_gemma":[0.001436821,0.000662406,0.001446428,0.000432641,0.0009893455,0.0011698,0.000395633,0.002820652,0.0008968303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001128,"about_ca_system_score_gemma":0.001741228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001420787,"about_ca_topic_score_gemma":0.003824442,"domain_scores_codex":[0.9993626,0.0003458112,0.00003721219,0.00009046207,0.00004643648,0.0001174351],"domain_scores_gemma":[0.9989963,0.000191472,0.0001793824,0.00006919231,0.00006183559,0.0005018592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8290792,0.06694072,0.008569016,0.0005476443,0.00119847,0.0003722434,0.0004053469,0.001913367,0.02854616,0.000144062,0.002617425,0.05966632],"study_design_scores_gemma":[0.5345514,0.4449579,0.015271,0.00003555585,0.0004878651,0.0002660452,0.00007582601,0.001351959,0.001644231,0.0001113062,0.001213275,0.00003369399],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957057,0.001050087,0.0003039411,0.0002382799,0.00006736946,0.00108173,0.0006932516,0.00006729664,0.0007923212],"genre_scores_gemma":[0.9920847,0.001094073,0.001380884,0.0006072724,0.0001915851,0.001459794,0.002057863,0.00002610321,0.001097782],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003000065,"threshold_uncertainty_score":0.01162696,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0949849504133424,"score_gpt":0.4589928688315748,"score_spread":0.3640079184182323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}